These results indicate that iNOS-derived NO in HFD conditions prevent hepatic fibrosis and inflammation, and the deficiency of iNOS strongly accelerates progression to NASH, independent of excessive lipid accumulation in the liver. Here, NOS2 is linked to metabolic dysfunction-associated steatohepatitis.